Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 396 entries
Sorted by: Best Match Show Resources per page
In Vivo Hypocholesterolemic Effect of MARDI Fermented Red Yeast Rice Water Extract in High Cholesterol Diet Fed Mice.

Evidence-based complementary and alternative medicine : eCAM

Yeap SK, Beh BK, Kong J, Ho WY, Mohd Yusof H, Mohamad NE, Hussin AB, Jaganath IB, Alitheen NB, Jamaluddin A, Long K.
PMID: 25031606
Evid Based Complement Alternat Med. 2014;2014:707829. doi: 10.1155/2014/707829. Epub 2014 Jun 16.

Fermented red yeast rice has been traditionally consumed as medication in Asian cuisine. This study aimed to determine the in vivo hypocholesterolemic and antioxidant effects of fermented red yeast rice water extract produced using Malaysian Agricultural Research and Development...

Cite
Yeap SK, Beh BK, Kong J, et al. In Vivo Hypocholesterolemic Effect of MARDI Fermented Red Yeast Rice Water Extract in High Cholesterol Diet Fed Mice. Evid Based Complement Alternat Med. 2014;2014:707829doi: 10.1155/2014/707829.
Yeap, S. K., Beh, B. K., Kong, J., Ho, W. Y., Mohd Yusof, H., Mohamad, N. E., Hussin, A. B., Jaganath, I. B., Alitheen, N. B., Jamaluddin, A., & Long, K. (2014). In Vivo Hypocholesterolemic Effect of MARDI Fermented Red Yeast Rice Water Extract in High Cholesterol Diet Fed Mice. Evidence-based complementary and alternative medicine : eCAM, 2014707829. https://doi.org/10.1155/2014/707829
Yeap, Swee Keong, et al. "In Vivo Hypocholesterolemic Effect of MARDI Fermented Red Yeast Rice Water Extract in High Cholesterol Diet Fed Mice." Evidence-based complementary and alternative medicine : eCAM vol. 2014 (2014): 707829. doi: https://doi.org/10.1155/2014/707829
Yeap SK, Beh BK, Kong J, Ho WY, Mohd Yusof H, Mohamad NE, Hussin AB, Jaganath IB, Alitheen NB, Jamaluddin A, Long K. In Vivo Hypocholesterolemic Effect of MARDI Fermented Red Yeast Rice Water Extract in High Cholesterol Diet Fed Mice. Evid Based Complement Alternat Med. 2014;2014:707829. doi: 10.1155/2014/707829. Epub 2014 Jun 16. PMID: 25031606; PMCID: PMC4083602.
Copy Download .nbib Format: NLM
Recent Advances in Molecular Genetics of Cardiovascular Disorders - Implications for Atherosclerosis and Diseases of Cellular Lipid Metabolism.

Pathology oncology research : POR

Schmitz G, Aslanidis C, Lackner KJ.
PMID: 11173654
Pathol Oncol Res. 1998;4(2):153-161.

Two developments in molecular genetics will profoundly influence our understanding and the diagnosis of cardiovascular disorders. First, the identification of genes responsible for monogenic and polygenic traits by analysis of e.g. large pedigrees and affected sib pairs provides invaluable...

Cite
Schmitz G, Aslanidis C, Lackner KJ. Recent Advances in Molecular Genetics of Cardiovascular Disorders - Implications for Atherosclerosis and Diseases of Cellular Lipid Metabolism. Pathol Oncol Res. 1998;4(2):153-161
Schmitz, G., Aslanidis, C., & Lackner, K. J. (1998). Recent Advances in Molecular Genetics of Cardiovascular Disorders - Implications for Atherosclerosis and Diseases of Cellular Lipid Metabolism. Pathology oncology research : POR, 4(2), 153-161.
Schmitz, Gerd, et al. "Recent Advances in Molecular Genetics of Cardiovascular Disorders - Implications for Atherosclerosis and Diseases of Cellular Lipid Metabolism." Pathology oncology research : POR vol. 4,2 (1998): 153-161.
Schmitz G, Aslanidis C, Lackner KJ. Recent Advances in Molecular Genetics of Cardiovascular Disorders - Implications for Atherosclerosis and Diseases of Cellular Lipid Metabolism. Pathol Oncol Res. 1998;4(2):153-161. PMID: 11173654.
Copy Download .nbib Format: NLM
[Evaluation of lipids, lipoproteins and apolipoproteins in the blood serum of children with type 1 diabetes].

Endokrynologia, diabetologia i choroby przemiany materii wieku rozwojowego : organ Polskiego Towarzystwa Endokrynologow Dzieciecych

Pac-Kozuchowska E, Szewczyk L, Witkowski D.
PMID: 12818127
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2002;8(1):23-7.

BACKGROUND: Children and youth with type 1 diabetes have a higher risk of atherosclerosis. Therefore all of the atherosclerosis risk factors should be observed in those children early. The disorders of lipid metabolism are characteristic and their intensification depends...

Cite
Pac-Kozuchowska E, Szewczyk L, Witkowski D. Zachowanie sie stezeń lipidów, lipoprotein i apolipoprotein w surowicy krwi u dzieci z cukrzyca typu 1. [Evaluation of lipids, lipoproteins and apolipoproteins in the blood serum of children with type 1 diabetes]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2002;8(1):23-7
Pac-Kozuchowska, E., Szewczyk, L., & Witkowski, D. (2002). Zachowanie sie stezeń lipidów, lipoprotein i apolipoprotein w surowicy krwi u dzieci z cukrzyca typu 1. [Evaluation of lipids, lipoproteins and apolipoproteins in the blood serum of children with type 1 diabetes]. Endokrynologia, diabetologia i choroby przemiany materii wieku rozwojowego : organ Polskiego Towarzystwa Endokrynologow Dzieciecych, 8(1), 23-7.
Pac-Kozuchowska, Elzbieta, et al. "Zachowanie sie stezeń lipidów, lipoprotein i apolipoprotein w surowicy krwi u dzieci z cukrzyca typu 1." [Evaluation of lipids, lipoproteins and apolipoproteins in the blood serum of children with type 1 diabetes]. Endokrynologia, diabetologia i choroby przemiany materii wieku rozwojowego : organ Polskiego Towarzystwa Endokrynologow Dzieciecych vol. 8,1 (2002): 23-7.
Pac-Kozuchowska E, Szewczyk L, Witkowski D. Zachowanie sie stezeń lipidów, lipoprotein i apolipoprotein w surowicy krwi u dzieci z cukrzyca typu 1. [Evaluation of lipids, lipoproteins and apolipoproteins in the blood serum of children with type 1 diabetes]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2002;8(1):23-7. Polish. PMID: 12818127.
Copy Download .nbib Format: NLM
Cardiovascular risk factors in young drug addicts.

Addiction biology

Berg JE, Høstmark AT.
PMID: 12893469
Addict Biol. 1996;1(3):297-302. doi: 10.1080/1355621961000124916.

Since the type of life-style often encountered in drug addicts is purported to influence their risk of cardiovascular disease, it seemed of interest to carry out a descriptive study on risk factors in young addicts. Twenty-four young intravenous drug...

Cite
Berg JE, Høstmark AT. Cardiovascular risk factors in young drug addicts. Addict Biol. 1996;1(3):297-302doi: 10.1080/1355621961000124916.
Berg, J. E., & Høstmark, A. T. (1996). Cardiovascular risk factors in young drug addicts. Addiction biology, 1(3), 297-302. https://doi.org/10.1080/1355621961000124916
Berg, J E, and Høstmark, A T. "Cardiovascular risk factors in young drug addicts." Addiction biology vol. 1,3 (1996): 297-302. doi: https://doi.org/10.1080/1355621961000124916
Berg JE, Høstmark AT. Cardiovascular risk factors in young drug addicts. Addict Biol. 1996;1(3):297-302. doi: 10.1080/1355621961000124916. PMID: 12893469.
Copy Download .nbib Format: NLM
Effects of ethanol on lipids and atherosclerosis.

Pathophysiology : the official journal of the International Society for Pathophysiology

Hannuksela ML, Rämet ME, Nissinen AE, Liisanantti MK, Savolainen MJ.
PMID: 15006415
Pathophysiology. 2004 Apr;10(2):93-103. doi: 10.1016/j.pathophys.2003.10.009.

Moderate alcohol consumption is associated with an increase in plasma high density lipoprotein (HDL) cholesterol concentration and a decrease in low density lipoprotein (LDL) cholesterol concentration. Changes in the concentration and composition of lipoproteins are estimated to account for...

Cite
Hannuksela ML, Rämet ME, Nissinen AE, et al. Effects of ethanol on lipids and atherosclerosis. Pathophysiology. 2004;10(2):93-103doi: 10.1016/j.pathophys.2003.10.009.
Hannuksela, M. L., Rämet, M. E., Nissinen, A. E., Liisanantti, M. K., & Savolainen, M. J. (2004). Effects of ethanol on lipids and atherosclerosis. Pathophysiology : the official journal of the International Society for Pathophysiology, 10(2), 93-103. https://doi.org/10.1016/j.pathophys.2003.10.009
Hannuksela, Minna L, et al. "Effects of ethanol on lipids and atherosclerosis." Pathophysiology : the official journal of the International Society for Pathophysiology vol. 10,2 (2004): 93-103. doi: https://doi.org/10.1016/j.pathophys.2003.10.009
Hannuksela ML, Rämet ME, Nissinen AE, Liisanantti MK, Savolainen MJ. Effects of ethanol on lipids and atherosclerosis. Pathophysiology. 2004 Apr;10(2):93-103. doi: 10.1016/j.pathophys.2003.10.009. PMID: 15006415.
Copy Download .nbib Format: NLM
Hepatocyte nuclear factor-4alpha and -1 small interfering RNA inhibits hepatocyte differentiation induced by extracellular matrix.

Hepatology research : the official journal of the Japan Society of Hepatology

Kimata T, Nagaki M, Tsukada Y, Ogiso T, Moriwaki H.
PMID: 16563856
Hepatol Res. 2006 May;35(1):3-9. doi: 10.1016/j.hepres.2006.01.011. Epub 2006 Mar 24.

Liver-specific genes and hepatocyte nuclear factor (HNF)-4alpha and -1 are coordinately regulated by extracellular matrix (ECM). However, still are unclear interactions between liver-specific genes and these liver-enriched transcription factors in the mechanism of hepatocyte differentiation regulated by ECM. To...

Cite
Kimata T, Nagaki M, Tsukada Y, et al. Hepatocyte nuclear factor-4alpha and -1 small interfering RNA inhibits hepatocyte differentiation induced by extracellular matrix. Hepatol Res. 2006;35(1):3-9doi: 10.1016/j.hepres.2006.01.011.
Kimata, T., Nagaki, M., Tsukada, Y., Ogiso, T., & Moriwaki, H. (2006). Hepatocyte nuclear factor-4alpha and -1 small interfering RNA inhibits hepatocyte differentiation induced by extracellular matrix. Hepatology research : the official journal of the Japan Society of Hepatology, 35(1), 3-9. https://doi.org/10.1016/j.hepres.2006.01.011
Kimata, Takayuki, et al. "Hepatocyte nuclear factor-4alpha and -1 small interfering RNA inhibits hepatocyte differentiation induced by extracellular matrix." Hepatology research : the official journal of the Japan Society of Hepatology vol. 35,1 (2006): 3-9. doi: https://doi.org/10.1016/j.hepres.2006.01.011
Kimata T, Nagaki M, Tsukada Y, Ogiso T, Moriwaki H. Hepatocyte nuclear factor-4alpha and -1 small interfering RNA inhibits hepatocyte differentiation induced by extracellular matrix. Hepatol Res. 2006 May;35(1):3-9. doi: 10.1016/j.hepres.2006.01.011. Epub 2006 Mar 24. PMID: 16563856.
Copy Download .nbib Format: NLM
Relation between low serum cholesteryl-ester transfer activity and abdominal aortic calcification in normolipidemic elderly subjects.

Archives of gerontology and geriatrics

Miyashita Y, Morimoto S, Fukuo K, Masuyama T, Yasuda O, Koh E, Tamatani M, Nakahashi T, Ogihara T.
PMID: 15374350
Arch Gerontol Geriatr. 1993 Jan-Feb;16(1):9-15. doi: 10.1016/0167-4943(93)90022-a.

We studied the relation between cholesteryl-ester transfer activity (CETA) and abdominal aortic calcification in elderly subjects. Compared with 10 young healthy subjects (mean +/- S.D. age, 27 +/-2 years) and to 26 elderly subjects without abdominal aortic calcification (79...

Cite
Miyashita Y, Morimoto S, Fukuo K, et al. Relation between low serum cholesteryl-ester transfer activity and abdominal aortic calcification in normolipidemic elderly subjects. Arch Gerontol Geriatr. 1993;16(1):9-15doi: 10.1016/0167-4943(93)90022-a.
Miyashita, Y., Morimoto, S., Fukuo, K., Masuyama, T., Yasuda, O., Koh, E., Tamatani, M., Nakahashi, T., & Ogihara, T. (1993). Relation between low serum cholesteryl-ester transfer activity and abdominal aortic calcification in normolipidemic elderly subjects. Archives of gerontology and geriatrics, 16(1), 9-15. https://doi.org/10.1016/0167-4943(93)90022-a
Miyashita, Y, et al. "Relation between low serum cholesteryl-ester transfer activity and abdominal aortic calcification in normolipidemic elderly subjects." Archives of gerontology and geriatrics vol. 16,1 (1993): 9-15. doi: https://doi.org/10.1016/0167-4943(93)90022-a
Miyashita Y, Morimoto S, Fukuo K, Masuyama T, Yasuda O, Koh E, Tamatani M, Nakahashi T, Ogihara T. Relation between low serum cholesteryl-ester transfer activity and abdominal aortic calcification in normolipidemic elderly subjects. Arch Gerontol Geriatr. 1993 Jan-Feb;16(1):9-15. doi: 10.1016/0167-4943(93)90022-a. PMID: 15374350.
Copy Download .nbib Format: NLM
Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis.

Biomarker insights

Kirmizis D, Koutoupa E, Tsiandoulas A, Valtopoulou A, Niavis G, Markou P, Barboutis K.
PMID: 19690648
Biomark Insights. 2007 Feb 07;1:185-92.

We designed the present case-control study in order to examine the validity of apolipoprotein (apo) A-I, B, apoB/apoA-I ratio and Lp(a) as alternative markers of cardiovascular morbidity in end-stage renal disease (ESRD) patients undergoing chronic hemodialysis (HD). Twenty-five HD...

Cite
Kirmizis D, Koutoupa E, Tsiandoulas A, et al. Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis. Biomark Insights. 2007;1:185-92
Kirmizis, D., Koutoupa, E., Tsiandoulas, A., Valtopoulou, A., Niavis, G., Markou, P., & Barboutis, K. (2007). Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis. Biomarker insights, 1185-92.
Kirmizis, Dimitrios, et al. "Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis." Biomarker insights vol. 1 (2007): 185-92.
Kirmizis D, Koutoupa E, Tsiandoulas A, Valtopoulou A, Niavis G, Markou P, Barboutis K. Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis. Biomark Insights. 2007 Feb 07;1:185-92. PMID: 19690648; PMCID: PMC2716782.
Copy Download .nbib Format: NLM
Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion.

Nutrition & metabolism

Sundaram M, Yao Z.
PMID: 20423497
Nutr Metab (Lond). 2010 Apr 27;7:35. doi: 10.1186/1743-7075-7-35.

Excess lipid induced metabolic disorders are one of the major existing challenges for the society. Among many different causes of lipid disorders, overproduction and compromised catabolism of triacylglycerol-rich very low density lipoproteins (VLDL) have become increasingly prevalent leading to...

Cite
Sundaram M, Yao Z. Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr Metab (Lond). 2010;7:35doi: 10.1186/1743-7075-7-35.
Sundaram, M., & Yao, Z. (2010). Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutrition & metabolism, 735. https://doi.org/10.1186/1743-7075-7-35
Sundaram, Meenakshi, and Yao, Zemin. "Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion." Nutrition & metabolism vol. 7 (2010): 35. doi: https://doi.org/10.1186/1743-7075-7-35
Sundaram M, Yao Z. Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr Metab (Lond). 2010 Apr 27;7:35. doi: 10.1186/1743-7075-7-35. PMID: 20423497; PMCID: PMC2873297.
Copy Download .nbib Format: NLM
Hepatitis C as a metabolic disease: Implication for the pathogenesis of NASH.

Hepatology research : the official journal of the Japan Society of Hepatology

Koike K.
PMID: 16202646
Hepatol Res. 2005 Oct;33(2):145-50. doi: 10.1016/j.hepres.2005.09.023. Epub 2005 Oct 03.

In addition to the link with development of hepatocellular carcinoma (HCC), hepatitis C virus (HCV) infection is associated with several extrahepatic manifestations such as essential mixed cryoglobulinemia, porphyria cutanea tarda or Sjögren's syndrome. A role of hepatic steatosis in...

Cite
Koike K. Hepatitis C as a metabolic disease: Implication for the pathogenesis of NASH. Hepatol Res. 2005;33(2):145-50doi: 10.1016/j.hepres.2005.09.023.
Koike, K. (2005). Hepatitis C as a metabolic disease: Implication for the pathogenesis of NASH. Hepatology research : the official journal of the Japan Society of Hepatology, 33(2), 145-50. https://doi.org/10.1016/j.hepres.2005.09.023
Koike, Kazuhiko. "Hepatitis C as a metabolic disease: Implication for the pathogenesis of NASH." Hepatology research : the official journal of the Japan Society of Hepatology vol. 33,2 (2005): 145-50. doi: https://doi.org/10.1016/j.hepres.2005.09.023
Koike K. Hepatitis C as a metabolic disease: Implication for the pathogenesis of NASH. Hepatol Res. 2005 Oct;33(2):145-50. doi: 10.1016/j.hepres.2005.09.023. Epub 2005 Oct 03. PMID: 16202646.
Copy Download .nbib Format: NLM
Rosuvastatin reduces non-high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia).

Journal of clinical lipidology

Blom DJ, Marais AD, Retterstøl K, Stein EA, Ycas J, Gu Z, Miller E.
PMID: 21291775
J Clin Lipidol. 2008 Dec;2(6):418-25. doi: 10.1016/j.jacl.2008.10.002. Epub 2008 Nov 01.

BACKGROUND: Dysbetalipoproteinemia is an uncommon genetic disorder characterized by accumulation of plasma remnant lipoproteins, severe mixed dyslipidemia, elevated apolipoprotein E levels, accelerated atherosclerosis, and premature cardiovascular disease.OBJECTIVE: To evaluate the efficacy and safety of rosuvastatin in patients with dysbetalipoproteinemia.METHODS:...

Cite
Blom DJ, Marais AD, Retterstøl K, et al. Rosuvastatin reduces non-high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia). J Clin Lipidol. 2008;2(6):418-25doi: 10.1016/j.jacl.2008.10.002.
Blom, D. J., Marais, A. D., Retterstøl, K., Stein, E. A., Ycas, J., Gu, Z., & Miller, E. (2008). Rosuvastatin reduces non-high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia). Journal of clinical lipidology, 2(6), 418-25. https://doi.org/10.1016/j.jacl.2008.10.002
Blom, Dirk J, et al. "Rosuvastatin reduces non-high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia)." Journal of clinical lipidology vol. 2,6 (2008): 418-25. doi: https://doi.org/10.1016/j.jacl.2008.10.002
Blom DJ, Marais AD, Retterstøl K, Stein EA, Ycas J, Gu Z, Miller E. Rosuvastatin reduces non-high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia). J Clin Lipidol. 2008 Dec;2(6):418-25. doi: 10.1016/j.jacl.2008.10.002. Epub 2008 Nov 01. PMID: 21291775.
Copy Download .nbib Format: NLM
Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia.

Journal of clinical lipidology

Davidson MH, Maki KC, Bays H, Carter R, Ballantyne CM.
PMID: 21291831
J Clin Lipidol. 2009 Oct;3(5):332-40. doi: 10.1016/j.jacl.2009.08.001. Epub 2009 Aug 31.

BACKGROUND: Prescription omega-3-acid ethyl esters (P-OM3) often are used for hypertriglyceridemic patients receiving statin therapy who have residual increases in atherogenic lipoprotein lipid levels. To date, limited information has been published regarding the effects of omega-3 fatty acid consumption...

Cite
Davidson MH, Maki KC, Bays H, et al. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol. 2009;3(5):332-40doi: 10.1016/j.jacl.2009.08.001.
Davidson, M. H., Maki, K. C., Bays, H., Carter, R., & Ballantyne, C. M. (2009). Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia. Journal of clinical lipidology, 3(5), 332-40. https://doi.org/10.1016/j.jacl.2009.08.001
Davidson, Michael H, et al. "Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia." Journal of clinical lipidology vol. 3,5 (2009): 332-40. doi: https://doi.org/10.1016/j.jacl.2009.08.001
Davidson MH, Maki KC, Bays H, Carter R, Ballantyne CM. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol. 2009 Oct;3(5):332-40. doi: 10.1016/j.jacl.2009.08.001. Epub 2009 Aug 31. PMID: 21291831.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 396 entries